Figure-1 (Fig 1)
Tyruko Injection
Product Images NDC 61314-543
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Tyruko (NDC 61314-543). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Sandoz Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Tyruko-carton (Tyruko 01)
This text provides detailed information about a medication called TYRUKO®, which is natalizumab-sztn injection used for intravenous infusion. Each 15 mL vial contains 300 mg of natalizumab-sztn along with other ingredients. It is advised to store the vial refrigerated at 2°C to 8°C, in the original carton to protect from light, and not to freeze or shake it. It is a single-dose vial that must be diluted prior to use, with any unused portion discarded. Pharmacists are instructed to ensure that each patient receives the enclosed Medication Guide. Recommended dosage details are available in the prescribing information. The medication is manufactured by Sandoz Inc. in the US, with a product of Poland and the latest revision mentioned as 01/2025.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
